Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C | Zendy

Elif Sargın Altunok | Zendy; Murat Sayan | Zendy; Sıla Akhan | Zendy; Bilgehan Aygen | Zendy; Orhan Yıldız | Zendy; Süda Tekin Koruk | Zendy; Reşit Mıstık | Zendy; Neşe Demirtürk | Zendy; Onur Ural | Zendy; Şükran Köse | Zendy; Aynur Aynıoğlu | Zendy; Fatime Korkmaz | Zendy; Gülden Ersöz | Zendy; Nazan Tuna | Zendy; Celal Ayaz | Zendy; Faruk Karakeçili | Zendy; Derya Keten | Zendy; Dilara İnan | Zendy; Saadet Yazıcı | Zendy; Safiye Koçulu | Zendy; Taner Yıldırmak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C

Author(s) -

Elif Sargın Altunok,

Murat Sayan,

Sıla Akhan,

Bilgehan Aygen,

Orhan Yıldız,

Süda Tekin Koruk,

Reşit Mıstık,

Neşe Demirtürk,

Onur Ural,

Şükran Köse,

Aynur Aynıoğlu,

Fatime Korkmaz,

Gülden Ersöz,

Nazan Tuna,

Celal Ayaz,

Faruk Karakeçili,

Derya Keten,

Dilara İnan,

Saadet Yazıcı,

Safiye Koçulu,

Taner Yıldırmak

Publication year - 2016

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2016.07.003

Subject(s) - telaprevir , boceprevir , drug resistance , medicine , resistance mutation , simeprevir , mutation , genotype , virology , protease inhibitor (pharmacology) , chronic hepatitis , pharmacology , biology , genetics , reverse transcriptase , polymerase chain reaction , gene , ribavirin , virus , viral load , antiretroviral therapy

Drug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C (HCV) drug associated resistance to oral antivirals.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research